✨
AI Summary
- Upadacitinib showed feasibility and efficacy in a trial for palmoplantar pustulosis.
- The JAK inhibitor met recruitment, adherence, and acceptability thresholds.
- Significant disease severity reduction was observed compared to historical placebo data.